GM-CSF gene-modifed cancer cell immunotherapies: Of mice and men

Kristen M. Hege, Karin Jooss, Andrew Mark Pardoll

Research output: Contribution to journalArticle

Abstract

GVAX cancer immunotherapies are composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division. Both autologous (patient specific) and allogeneic (non-patient specific) GVAX platforms have been evaluated either as single agents or in combination with other immunomodulatory strategies. Many early-phase clinical trials have now been completed. Results have consistently demonstrated a favorable safety profile manifested primarily by injection site reactions and flu-like symptoms. Consistent evidence of immune activation and clinical activity, including radiologic tumor regressions, has been seen across multiple cancer indications in both early- and late-stage disease. Phase 3 trials evaluating an allogeneic GVAX immunotherapy product in prostate cancer are under way.

Original languageEnglish (US)
Pages (from-to)321-352
Number of pages32
JournalInternational Reviews of Immunology
Volume25
Issue number5-6
DOIs
StatePublished - Dec 1 2006

Fingerprint

Neoplasm Genes
Granulocyte-Macrophage Colony-Stimulating Factor
Immunotherapy
Neoplasms
Cell Division
Prostatic Neoplasms
Clinical Trials
Cytokines
Safety
Injections

Keywords

  • Cancer vaccine
  • GM-CSF
  • GVAX
  • Immunotherapy

ASJC Scopus subject areas

  • Immunology

Cite this

GM-CSF gene-modifed cancer cell immunotherapies : Of mice and men. / Hege, Kristen M.; Jooss, Karin; Pardoll, Andrew Mark.

In: International Reviews of Immunology, Vol. 25, No. 5-6, 01.12.2006, p. 321-352.

Research output: Contribution to journalArticle

@article{8950128c9d6343adbc6f39e6b49c8052,
title = "GM-CSF gene-modifed cancer cell immunotherapies: Of mice and men",
abstract = "GVAX cancer immunotherapies are composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division. Both autologous (patient specific) and allogeneic (non-patient specific) GVAX platforms have been evaluated either as single agents or in combination with other immunomodulatory strategies. Many early-phase clinical trials have now been completed. Results have consistently demonstrated a favorable safety profile manifested primarily by injection site reactions and flu-like symptoms. Consistent evidence of immune activation and clinical activity, including radiologic tumor regressions, has been seen across multiple cancer indications in both early- and late-stage disease. Phase 3 trials evaluating an allogeneic GVAX immunotherapy product in prostate cancer are under way.",
keywords = "Cancer vaccine, GM-CSF, GVAX, Immunotherapy",
author = "Hege, {Kristen M.} and Karin Jooss and Pardoll, {Andrew Mark}",
year = "2006",
month = "12",
day = "1",
doi = "10.1080/08830180600992498",
language = "English (US)",
volume = "25",
pages = "321--352",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - GM-CSF gene-modifed cancer cell immunotherapies

T2 - Of mice and men

AU - Hege, Kristen M.

AU - Jooss, Karin

AU - Pardoll, Andrew Mark

PY - 2006/12/1

Y1 - 2006/12/1

N2 - GVAX cancer immunotherapies are composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division. Both autologous (patient specific) and allogeneic (non-patient specific) GVAX platforms have been evaluated either as single agents or in combination with other immunomodulatory strategies. Many early-phase clinical trials have now been completed. Results have consistently demonstrated a favorable safety profile manifested primarily by injection site reactions and flu-like symptoms. Consistent evidence of immune activation and clinical activity, including radiologic tumor regressions, has been seen across multiple cancer indications in both early- and late-stage disease. Phase 3 trials evaluating an allogeneic GVAX immunotherapy product in prostate cancer are under way.

AB - GVAX cancer immunotherapies are composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then irradiated to prevent further cell division. Both autologous (patient specific) and allogeneic (non-patient specific) GVAX platforms have been evaluated either as single agents or in combination with other immunomodulatory strategies. Many early-phase clinical trials have now been completed. Results have consistently demonstrated a favorable safety profile manifested primarily by injection site reactions and flu-like symptoms. Consistent evidence of immune activation and clinical activity, including radiologic tumor regressions, has been seen across multiple cancer indications in both early- and late-stage disease. Phase 3 trials evaluating an allogeneic GVAX immunotherapy product in prostate cancer are under way.

KW - Cancer vaccine

KW - GM-CSF

KW - GVAX

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33845721818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845721818&partnerID=8YFLogxK

U2 - 10.1080/08830180600992498

DO - 10.1080/08830180600992498

M3 - Article

C2 - 17169779

AN - SCOPUS:33845721818

VL - 25

SP - 321

EP - 352

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 5-6

ER -